Restorative functions of Autologous Stem Leydig Cell transplantation in a Testosterone-deficient non-human primate model

Kai Xia¹², Hong Chen², Jiancheng Wang²⁸, Xin Feng¹², Yong Gao³, Yi Wang², Rongda Deng¹, Chunxing Wu¹, Peng Luo¹, Min Zhang¹², Chao Wang², Yong Zhang⁷, Yadong Zhang¹, Guihua Liu⁴, Xiang’an Tu¹, Xiangzhou Sun¹, Weiqiang Li²³, Qiong Ke⁷, Chunhua Deng¹⁵ and Andy Peng Xiang²⁶

¹. Department of Andrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
². Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou, Guangdong, China.
³. Reproductive Medicine Center, The Key Laboratory for Reproductive Medicine of Guangdong Province, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
⁴. Center for Reproductive Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
⁵. Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
⁶. Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
⁷. Department of Nuclear Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
⁸. Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.

*These authors made equal contributions to this work.

Corresponding authors: Andy Peng Xiang (E-mail: xiangp@mail.sysu.edu.cn), Chunhua Deng (E-mail: dch0313@163.com) and Qiong Ke (E-mail: kqbear@163.com).

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2020.04.09; Accepted: 2020.05.20; Published: 2020.07.09

Abstract

Rationale: Stem Leydig cells (SLCs) transplantation can restore testosterone production in rodent models and is thus a potential solution for treating testosterone deficiency (TD). However, it remains unknown whether these favorable effects will be reproduced in more clinically relevant large-animal models. Therefore, we assessed the feasibility, safety and efficacy of autologous SLCs transplantation in a testosterone-deficient non-human primate (NHP) model.

Methods: Cynomolgus monkey SLCs (CM-SLCs) were isolated from testis biopsies of elderly (> 19 years) cynomolgus monkeys by flow cytometry. Autologous CM-SLCs were injected into the testicular interstitium of 7 monkeys. Another 4 monkeys were injected the same way with cynomolgus monkey dermal fibroblasts (CM-DFs) as controls. The animals were then examined for sex hormones, semen, body composition, grip strength, and exercise activity.

Results: We first isolated CD271⁺ CM-SLCs which were confirmed to expand continuously and show potential to differentiate into testosterone-producing Leydig cells (LCs) in vitro. Compared with CM-DFs transplantation, engraftment of autologous CM-SLCs into elderly monkeys could significantly increase the serum testosterone level in a physiological pattern for 8 weeks, without any need for immunosuppression. Importantly, CM-SLCs transplantation recovered spermatogenesis and ameliorated TD-related symptoms, such as those related to body fat mass, lean mass, bone mineral density, strength and exercise capacity.

Conclusion: For the first time, our short-term observations demonstrated that autologous SLCs can increase testosterone levels and ameliorate relevant TD symptoms in primate models. A larger cohort with long-term follow-up will be required to assess the translational potential of autologous SLCs for TD therapy.

Key words: Stem Leydig cell; Autologous; Transplantation; Testosterone deficiency; Non-human primate
Introduction

Testosterone deficiency (TD) occurs in approximately 20% of men aged 40 to 79 years, and the incidence increases with age [1-4]. The clinical features of TD include sexual dysfunction [5], obesity [2], muscle weakness [6, 7], osteoporosis [8, 9] and others. Epidemiological studies have suggested that low testosterone levels are associated with multiple diseases and deteriorated quality of life [10, 11]. Exogenous testosterone replacement therapy (TRT) is a straightforward treatment for male TD [4, 10, 12] but may cause a series of adverse effects, such as stroke [13], heart attack [14] and prostate tumorigenesis [15, 16]. More importantly, this treatment disrupts the hypothalamic-pituitary-gonadal axis (HPG axis) [17], reducing the intratesticular testosterone concentration and disturbing spermatogenesis [18-20]; it therefore fails to meet the requirements of individualized treatment [11], especially given that the physiological testosterone level varies across individuals [21]. Thus, we need to explore promising new approaches for testosterone supplementation in a physiological pattern.

Leydig cells (LCs) are the primary source of circulating testosterone. However, their function is impaired in aged individuals, which appears to be due to a reduction in steroidogenic capacity per LC [22]. In addition, the total number of LCs was reported to decline over 40% between young (20-48 years old) and aged (50-76 years old) men [23]. Collectively, these studies suggested that aging-associated TD is attributed to not only impaired function but also a reduced number of LCs, while hypothalamic-pituitary function remains relatively unaffected [24]. In this context, transplantation of LCs seems to be an ideal candidate for physiological and long-acting testosterone delivery [25-27]. However, the limited proliferative capacity of adult LCs has restricted their translational application. Stem Leydig cells (SLCs), with the ability to proliferate and differentiate into LCs, could be a potential replacement [28-30]. Transplanted rodent SLCs have been shown to replace damaged or senescent LCs and restore testosterone production [31-34]. Thus, SLCs are considered to be a favorable cell source for the treatment of TD. Very recently, we showed for the first time that CD271+ (p75 neurotrophin receptor)-positive cells in human testes from young donors (18-32 years of age) have the characteristics of SLCs. Importantly, transplanted CD271+ SLCs were shown to restore testosterone production in a circadian rhythm and promote the recovery of spermatogenesis in a LC-disrupted model in rats [35]. These findings provide new insights into the clinical application of SLCs.

Autologous stem cell transplantation overcomes the current limitations posed by allogeneic donor cells and raises the enticing possibility that adult stem cells could be used to autologously replace diseased or damaged tissue [36-38]. It is not yet known whether SLCs can be isolated and propagated from elderly patients with the goal of treating age-related TD with autologous transplantation. Furthermore, it remains unclear whether the favorable testosterone restoration effects seen in small-animal models will be reproduced in more clinically relevant large-animal models. Non-human primates (NHPs) are similar to humans in size, behavior, physiology, biochemistry, structure and organ function [39, 40]. Researches on NHPs can directly address relevant and challenging translational aspects of cell transplantation therapy and form a translational bridge from small-animal models to humans [41]. Previous studies have demonstrated that NHP models offer unique opportunities to develop various stem cell-based therapeutic interventions, including those based on spermatogonial stem cells (SSCs) [42], pluripotent stem cell-derived cardiomyocytes [43], mesenchymal stem cells [44] and neural stem cells [45]. Using a cynomolgus monkey model, Morizane et al. showed that compared with allogeneic grafts, the autologous transplantation of iPSC-derived neural cells is advantageous for minimizing the immune response in the brain [38]. Male cynomolgus monkeys (Macaca fascicularis) show characteristic age-associated physiological changes comparable to those of human males [46-48], which makes them an ideal animal model for translational research, such as developing appropriate testosterone supplementation paradigms and evaluating the potential of stem cell transplantation in this context [49, 50]. Thus, preclinical assessment of the feasibility, safety and efficacy of autologous SLCs transplantation in NHP models of TD will be an important step in determining the translational potential of this cell therapy.

Methods

Animals

8-week-old male immunodeficient NCG mice (Nanjing Biomedical Research Institute of Nanjing University) were used for our analysis of tumorigenicity. The mice were maintained under controlled temperature (24 ± 1°C) and relative humidity (50-60%), with a 12-h light/12-h dark cycle and free access to a standard rodent diet and drinking water. Male cynomolgus monkeys (Macaca fascicularis; Blooming Spring Biological Technology Development
Co., Ltd.) were used for experiments. The details are specified in Table S1. All monkeys were housed at the Blooming Spring Biological Technology Development Co., Ltd., which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All animal experiments were carried out using protocols approved by the Ethics Committee of Zhongshan School of Medicine, Sun Yat-sen University (No. 2018-202), and the ICE for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University (No. 2019-013).

Isolation and culture of CM-SLCs from donor monkey testes

Testis tissue samples were collected from cynomolgus monkeys by subcapsular biopsy [51]. Less than 1% of the testicular parenchyma was removed (0.4-0.6 g) with puncturing forceps, which were applied to the lateral side of the tests. SLCs were isolated as previously reported [32]. In detail, the interstitial cells were dissociated from the seminiferous tubules by digestion with 1 mg/mL collagenase type IV (Gibco, Grand Island, NY, USA) in Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12 (DMEM/F12; 1:1, Gibco, Grand Island, NY, USA) at 37°C for 15 min. DMEM/F12 containing 5% fetal bovine serum (FBS, HyClone, Logan, UT, USA) was added to stop the digestion, and each sample was filtered through a 45 μm filter. The samples were centrifuged at 250 g at 4°C for 4 min, and the pellet was washed twice with phosphate-buffered saline (PBS) and then incubated with AF647-conjugated anti-CD271 (BD Biosciences, Franklin Lakes, NJ, USA) and isotype antibody (BD Bioscience) in the dark for 15 min. The CD271+ cells were enriched by flow cytometry using an Influx Cell Sorter (BD Bioscience). The expansion medium was a modified version of the previously published recipe [35] and consisted of DMEM/F12 (Gibco) supplemented with 1% nonessential amino acids (NEAA, Gibco), insulin-transferrin-sodium selenite (ITS, Gibco), N2 (Gibco), 2% B27 (Gibco), 20 ng/mL basic fibroblast growth factor (bFGF, PeproTech, Rocky Hill, NJ, USA), epidermal growth factor (EGF, PeproTech), platelet-derived growth factor-BB (PDGF-BB, PeproTech), oncostatin M (OSM, PeproTech), 1 ng/mL leukemia inhibitory factor (LIF, Millipore, Bedford, MA, USA), 1 nM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), and 0.1 mM β-mercaptoethanol (Gibco). The cultures were kept at 37°C in a humidified 5% CO₂ water-jacketed incubator (Thermo Fisher, Marietta, OH, USA), and the medium was changed every 3 days.

Cell proliferation assay

Cell proliferation was assessed using our previously reported method [35]. Cells at different passages (P5, P10, P15, and P20) were seeded into 24-well plates at a density of 1×10⁴ cells/well. Cell proliferation was examined at set times using a Cellometer Auto T4 automated cell counter (Nexcelom Bioscience, Lawrence, MA, USA).

Colony formation assay

Colony formation was assessed using our previously reported method [32]. CM-SLCs were dissociated into a single-cell suspension and diluted to a density of 500 cells/mL, and 2 µL of the diluted cell suspension and 150 µL of expansion medium were plated in each well of a 96-well plate (Corning, Tewksbury, MA, USA). Wells containing only one cell were marked and observed daily. Spheres were defined as free-floating spherical structures with a diameter > 50 μm.

Multilineage differentiation of CM-SLCs in vitro

For osteogenic, adipogenic and chondrogenic differentiation, CD271⁺ cells were cultured in differentiation-inducing medium for 2-4 weeks and analyzed by staining with Alizarin Red (Sigma-Aldrich), Oil Red O (Sigma-Aldrich) and Toluidine Blue (Sigma-Aldrich), respectively, as previously described [52]. The expression levels of lineage-specific genes were analyzed by RT-PCR, including alkaline phosphatase (ALP), secreted protein acidic and cysteine rich (SPARC) and runt-related transcription factor 2 (RUNX2) for osteogenesis, fatty acid-binding protein 4 (FABP4) and peroxisome proliferator activated receptor γ (PPARγ), and collagen type 2 alpha 1 chain (COL2A1) and aggrecan (ACAN) for chondrogenesis (primers are listed in Table S4).

LCs differentiation of CM-SLCs in vitro

For LCs lineage differentiation, the SLCs were plated in fresh differentiation-inducing medium containing phenol red-free DMEM/F12 (Gibco), 2% FBS (HyClone), 1 ng/mL luteinizing hormone (LH, R&D, Minneapolis, MN, USA), 1 nM thyroid hormone (Sigma-Aldrich), 10 ng/mL platelet-derived growth factor-ΑΑ (PDGF-ΑΑ, PeproTech), 50 ng/mL insulin-like growth factor 1 (IGF1, PeproTech), and 1% ITS (Gibco) and incubated for up to 28 days as previously described [52]. Cell culture supernatants were collected for testosterone detection at the indicated time points. Differentiation was confirmed by immunostaining and RT-PCR for LCs lineage markers (primers and antibodies are listed in Table S4-5).
Identification of TD cynomolgus monkeys

To screen for the cynomolgus monkey TD model, 30 elderly monkeys (19 to 23 years old) were initially included [40]. Blood samples were collected at 9-10 a.m. three times a week, and the levels of total testosterone (TT) and free testosterone (FT) were measured [53]. Based on the obtained results, 11 monkeys (TT < 10 ng/mL and FT < 0.25 ng/mL) were enrolled in the study. The animals were randomly assigned to two groups: group 1 received CM-DFs transplantation (M1-M4, n=4), while group 2 received CM-SLCs transplantation (M5-M11, n=7) (a more detailed description is provided in Table S1).

Lentiviral treatment of transplanted cells

For autologous transplantation, CM-SLCs or CM-DFs were treated with lentiviruses encoding red fluorescent protein (RFP). The lentiviral expression vector was designated pLent-CAG-mCherry-P2A-Puro (Vigene Biosciences, Rockville, MD, USA).

Cell transplantation

The cell transplantation procedure was modified from the previously described method [42]. Cells were digested and suspended at approximately 3×10^7 cells/mL in PBS containing a 20% concentration of the microbubble ultrasound contrast agent SonoVue (Bracco Imaging, HW, UK) in a total volume of 500 µL. Cell transplantation was performed using ultrasound-guided testicular injections (Movie S1). For this purpose, a 13-MHz linear superficial probe was used to visualize the testis on an ultrasound machine Logiq E9 (GE, Boston, MA, USA) and guide a 25G spinal needle into the testis.

Immunofluorescence staining

For immunofluorescence staining of cultured cells, the cells were fixed with 4% paraformaldehyde (PFA, Phygene, Fujian, China) for 15 min, permeabilized with 0.2% Triton X-100 (Sigma-Aldrich) for 15 min and blocked with 3% bovine serum albumin (BSA, Sigma-Aldrich) for 30 min at room temperature, as described previously [32]. These cells were incubated overnight with the relevant primary antibodies at 4-8°C. Then, the cells were washed with PBS and then incubated with the appropriate secondary antibodies for 45 min at room temperature. Nuclei were counterstained with DAPI (Gibco) for 5 min at room temperature. For immunofluorescence staining of monkey testes, the tissues were fixed in 4% PFA (Phygene), dehydrated with 30% sucrose (Sangon Biotech, Shanghai, China), and sectioned at a thickness of 10-50 µm. The sections were permeabilized for 30 min using 0.2% Triton X-100 (Sigma-Aldrich), blocked with 3% BSA (Sigma-Aldrich) in PBS for 45 min at room temperature and then incubated overnight with the relevant primary antibodies. The sections were then washed with PBS, incubated with the appropriate secondary antibodies for 45 min at room temperature, and co-stained with DAPI for 5 min (antibodies are listed in Table S5). Images were captured with an LSM800 confocal microscope (Zeiss, Jena, Germany) and a Dragonfly CR-DFLY-202540 (Andor Technology, Belfast, UK).

RT-PCR analysis

The total RNA fraction was extracted using a RNeasy Mini kit (Qiagen, Germantown, MD, USA) and reverse-transcribed using a High-Capacity RNA-to-cDNA™ Kit (Thermo Fisher). The obtained mRNA (1 µg) was incubated with 1× RT Buffer Mix and 1× RT Enzyme Mix. The reaction was incubated at 37°C for 60 min to generate cDNA, and then the reaction was stopped by heating to 95°C for 5 min and held at 4°C. Standard PCR experiments were performed using Taq DNA polymerase (NEB, Ipswich, MA, USA), and the relevant primers are listed in Table S4.

Karyotype analysis

G-band chromosomal analysis was performed by DAAN Gene Co., Ltd.

Tumorigenesis assay

Tumorigenesis was assessed as previously reported [54]. Expanded CM-SLCs or MA-10 Leydig tumor cells were suspended in 200 µL of PBS and injected subcutaneously into immunodeficient NCG mice (Nanjing Biomedical Research Institute of Nanjing University). Tissues were harvested for analysis at the time of tumor detection or at 3 months post injection if no detectable tumor formed.

Safety evaluation

Total testosterone levels, high-sensitivity C-reactive protein (Hs-CRP), hematological parameters (white blood cell, neutrophil, lymphocyte, monocyte, eosinophil, basophil, red blood cell, hemoglobin and platelet counts) were measured at baseline and at weeks 2 and 4 post testicular biopsy. Hematological parameters (white blood cell, neutrophil, lymphocyte, monocyte, eosinophil, basophil, red blood cell, hemoglobin and platelet counts), liver function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, cholinesterase, total protein, globulin, albumin, prealbumin, total bilirubin, direct bilirubin, indirect bilirubin, total bile acid, lactate dehydrogenase and γ-glutamyl transferase levels), kidney function (urea, uric acid and creatinine levels), heart function (creatine kinase, creatinine kinase isoenzyme and
hydroxybutyrate dehydrogenase levels) and tumor markers (alpha-fetoprotein, \( \beta \)-human chorionic gonadotropin and prostate-specific antigen) were measured at baseline and at weeks 4 and 8 post transplantation. All laboratory measurements were performed with standard autoanalyzer methods at the First Affiliated Hospital of Sun Yat-sen University.

**Sex hormone concentration assay**

To evaluate testosterone production after cell transplantation, blood samples were collected from the upper limb veins at weeks 0, 1, 2, 3, 4, 6, 8, 10 and 12 after cell transplantation. To test whether the testosterone level exhibited a circadian rhythm after CM-SLCs transplantation, M6 and M8 were chosen randomly to represent the group. Eight weeks after transplantation, blood samples were taken over a 36-h period at 08:00, 14:00, and 20:00 and 02:00, 08:00, 14:00, and 20:00 the next day. To test whether testosterone secretion was modulated by the HPG axis [17], M6 and M8 were subcutaneously administered decapeptyl (5 μg/kg/day) (Ipsen Pharma, Boulogne-Billancourt, France) for 28 consecutive days from 8 weeks after CM-SLCs transplantation. Blood samples were collected on days 0, 1, 4, 7, 10, 15, 20 and 25 post injection. Centrifugation was performed to obtain serum samples (3000 g, 10 min), which were stored at -80°C until analysis [55]. ELISA kits were used to analyze serum testosterone (R&D) and luteinizing hormone (Cusabio, Wuhan, Hubei, China). Absorbance at 450 nm was determined using an ELISA microtiter plate reader (Tecan, TECAN, SunriseTM, Männedorf, Switzerland). The hormone concentrations were calculated by reference to standard curves, which were constructed by graphing the absorbance of each reference standard against its corresponding concentration.

**Semen collection and analysis**

Semen samples from experimental animals were analyzed at weekly intervals before and after cell transplantation as previously described [56]. The samples were collected into sterile collection tubes and allowed to liquefy at 37°C for 30 min before evaluation. The volume was recorded, and the liquid fraction was resuspended in 90 μL of 37°C Tyrode albamin lactate pyruvate (TALP)-HEPES with BSA (Sigma-Aldrich) and centrifuged at 130-150 g for 10 min. The sample was washed and resuspended, and then the sperm count and concentration were measured on a hemocytometer. The percentage of motility was determined from duplicate counts of 100 sperm performed using a phase-contrast microscope (Leica, Wetzlar, Germany).

**Body composition assessment**

Dual-energy X-ray absorptiometry machine Discovery A (Hologic, Bedford, MA, USA) was used to assess total body fat, lean tissue mass and bone mineral density, as previously described [5, 9, 57]. Measurements were taken at baseline and at weeks 8-10 of the study. This technique yields data for fat mass, lean mass and bone mineral density for the total body and definable regions of interest. For scans, anesthesia was induced and maintained by intramuscular injection of ketamine (2 mg/kg) (CAHG, Beijing, China).

**Grip strength evaluation**

Grip strength was measured using a method adapted from those previously described for rodents and marmosets [58]. For each evaluation, a monkey entered the cage (2 feet long × 2 feet wide × 3 feet high), and grip strength was assessed during retrieval of food objects placed in a cup in front of the cage. Grip strength was recorded with a digital push-pull gauge (Handpi, Leqing, Zhejiang, China) connected to the food cup. The procedure was repeated at least five times per individual, and the maximum force was recorded for each grip attempt with both hands. The highest measurement within the testing session was considered to be the maximum grip strength of the animal at that time.

**Exercise activity assessment**

Exercise activity was evaluated weekly throughout the study using an open-field task modified from those previously described by other groups [45]. For each assessment, a monkey entered the open-field-testing enclosure (2 feet long × 2 feet wide × 7 feet high), and climbing was assessed during retrieval of food objects placed in a cup hanging at a 6 feet height in front of the cage. Assessments in this open field were performed with two observers: one videotaped the session, and one recorded the climbing distance and time on a scoring sheet. The videos were used to confirm the live scoring data. All assessments were performed without knowledge of group inclusion.

**Statistical analysis**

All results represent data from at least three independent experiments and are expressed as the mean ± sem. Statistical analyses were performed using GraphPad Prism v6.0c (GraphPad software). All statistical comparisons were made using Student's t-test or one-way ANOVA. Differences of \( P < 0.05 \) were considered significant.
Results

Isolation, characterization and long-term culture of CD271+ cells from testis biopsies of elderly cynomolgus monkeys

The isolation of SLCs from primary tissue has been hampered by the limited selectivity of the available markers [29, 59]. We previously demonstrated that CD271 (p75 neurotrophin receptor) can be used as a cell surface marker for identifying and isolating SLCs from human testes [35]. To further verify whether it could be used as a putative marker for isolating SLCs from NHPs, we first examined the CD271 expression pattern in the testes of cynomolgus monkeys. Consistent with our previous findings, CD271+ cells were located in the interstitium of the testis, co-expressed the known SLCs marker Nestin, and showed negligible co-expression of the mature LCs lineage markers 3-beta-hydroxysteroid dehydrogenase (3β-HSD) and steroidogenic acute regulatory protein (StAR) (Figure S1A). Moreover, we observed that CD271 expression gradually decreased with age until the signal was barely detectable in the testicular interstitium of aged monkeys (19 to 23 years old) (Figure S1B).

To investigate whether SLCs could be isolated from elderly monkey testes using CD271 as a putative surface marker, we obtained testicular biopsies [60] (less than 1% testis tissue) (Table S1) from 11 elderly male cynomolgus monkeys (Figure 1A). There were no significant abnormalities in TT, Hs-CRP or hematological parameters at weeks 2 and 4 after testicular biopsy (Table S2). CD271+ cells were isolated by flow cytometry (Figure 1B) and seeded in expansion medium. After 1 day of culture, most cells adhered to the plastic wells. When the adherent cells had propagated to 70-80% confluence, we dissociated these cells and transferred them to a new plate for further expansion. The CD271+ cells formed small spheres, which subsequently became floating spheres and showed proliferative ability (Figure 1C and S3A). As control cells, we also isolated dermal fibroblasts (DFs) from each member of the cohort.

Immunofluorescence staining showed that the cytospheres of cultured CD271+ cells expressed Nestin and PDGFRα but not the LCs lineage markers StAR and 3β-HSD (Figure 1D) at passage 5 (P5). Cultured CD271+ cells of different passages (P5, P10, P15, and P20) did not show any significant difference in clonogenic efficiency (Figure 1E-F), proliferation rate (Figure 1G) or population-doubling time (Figure 1H), indicating that these cells were highly clonogenic and exhibited self-renewal capacity in vitro. More importantly, we did not observe any obvious chromosomal elimination, displacement or imbalance after long-term culture (Figure S3C). When the CD271+ cells of P5 or P20 were inoculated subcutaneously into 8-week-old immunodeficient NCG mice, we failed to observe any sign of tumorigenicity 3 months later; in contrast, control mice injected with MA-10 Leydig tumor cells exhibited efficient formation of tumors (100%) (Figure S3D).

To investigate their potential to differentiate into LCs in vitro, CD271+ cells were cultured in differentiation medium. The differentiated cells expressed LCs-related steroidogenic enzymes, including StAR, 3β-HSD, cytochrome p450 family 11 subfamily A member 1 (CYP11A1), 17-beta-hydroxysteroid dehydrogenase (17β-HSD), luteinizing hormone receptor (LHR) and the nuclear transcription factor steroidogenic factor 1 (SF-1), as determined by immunofluorescence staining (Figure 1J and S2) and RT-PCR analysis (Figure 1K). Examination of cell culture supernatants collected at different time points revealed that testosterone synthesis gradually increased over time following the LCs differentiation of CD271+ cells (Figure 1I). After long-term culture (P20), the CD271+ cells retained their potential to differentiate into LCs (Figure S3B). Furthermore, these cells could differentiate into osteogenic, adipogenic and chondrogenic lineages (Figure S4). Due to their self-renewal and multiple differentiation potential, we designated these CD271+ cells as cynomolgus monkey SLCs (CM-SLCs).

Autologous transplantation of CM-SLCs partially recovers testosterone production

Aging is generally associated with a progressive decline in the biosynthesis of testosterone by LCs [25, 61]. Here, we performed autologous transplantation experiments to investigate whether CM-SLCs could differentiate into LCs in vivo and increase testosterone levels in a TD monkey model (Figure 2A). We screened 30 elderly monkeys three times for the TT and FT (see Methods) and then enrolled 11 monkeys that were 19 to 23 years old and had conditions indicative of TD (TT < 10 ng/mL and FT < 0.25 ng/mL). The animals were randomly divided into two groups: group 1 received CM-DFs transplantation (n = 4), while group 2 received CM-SLCs transplantation (n = 7) (Table S1). Cells were injected into the interstitium of the testes by ultrasound-guided testicular injection (Movie S1). Using this approach, we introduced 500 μL of cell suspension into per testis of each recipient. The cell numbers injected per testis ranged from 11.5 to 21.3 × 10⁶ cells (Table S1). We failed to observe any significant acute or chronic adverse effects at weeks 4 and 8 after transplantation of autologous CM-SLCs (Table S3).
No animal in this study received any immunosuppressive treatments during the duration of the study.
Figure 2. CM-SLCs transplantation recovers testosterone levels in monkeys with TD. (A) Schematic of the experimental procedure used for cell transplantation. (B-D) The concentrations of total testosterone (B), free testosterone (C), and bioavailable testosterone (D) were detected at the indicated time points in both groups. (E) Total testosterone/luteinizing hormone was measured at the indicated time points in both groups. (F) The cynomolgus monkeys (M6 and M8) in the CM-SLCs transplanted group appeared to exhibit a circadian rhythm of testosterone secretion. (G) The testosterone secretion ability of CM-SLCs monkeys (M6 and M8) was suppressed by decapeptyl treatment. Data are expressed as the mean ± sem and were analyzed by Student’s t-test; * P < 0.05, ** P < 0.01.

Blood samples were collected at the indicated time points after transplantation (Figure 2A). Our analysis revealed that the serum concentrations of TT significantly increased from 6.28 ± 0.44 ng/mL before transplantation to 12.67 ± 2.26 ng/mL at week 4 and slowly decreased beyond 8 weeks post transplantation of CM-SLCs (Figure 2B). More importantly, the serum concentrations of FT (Figure 2C) and bioavailable testosterone (BT) (Figure 2D), which is currently considered to be the gold standard for the diagnosis of TD in elderly men [2, 62], were also increased compared with those observed in the CM-DFs group. Moreover, the ratio of TT to luteinizing hormone (LH), which is a marker for LCs function [63], was increased significantly at weeks 4-8 after CM-SLCs transplantation (Figure 2E). 8 weeks after CM-SLCs transplantation, LH decreased significantly (Figure S5).

The circulating concentration of testosterone is regulated by the HPG axis [55, 64]. Thus, the ideal treatment for TD should provide physiological testosterone levels, exhibit the appropriate circadian rhythm and be modulated by the HPG axis [35, 52]. In the present study, two randomly selected cynomolgus
monkeys transplanted with autologous CM-SLCs (M6 and M8) appeared to display a normal daily rhythm of testosterone secretion (Figure 2F). When these subjects were administered decapreyl [52], an agonist of gonadotropin-releasing hormone (GnRHa), the testosterone concentrations peaked at day 1 and dramatically decreased thereafter (Figure 2G), suggesting that the transplanted CM-SLCs could be regulated by the HPG axis [52]. Taken together, these results demonstrate that autologous CM-SLCs transplantation could partially recover testosterone production with physiological properties.

**Transplanted CM-SLCs colonize the interstitium and differentiate to LCs in vivo**

To investigate the in vivo fate of the transplanted CM-SLCs, we collected unilateral testis samples from one randomly chosen member of each group (M2 and M5) at weeks 8 and 12 after transplantation, respectively. To distinguish the transplanted cells and their progeny from endogenous cells, we transduced the donor cells with a lentiviral vector expressing mCherry (RFP) driven by the CAG promoter and found that RFP expression did not alter the characteristics of the transplanted cells (data not shown). Immunofluorescence staining showed that the RFP+ cells in the CM-SLCs transplantation group were localized exclusively within the interstitium of the testis sample and expressed LCs-specific markers, including StAR (20.12 ± 1.36%), 3β-HSD (23.03 ± 0.88%) and CYP11A1 (22.15 ± 1.57%) (Figure 3A and S7). These results indicate that some of the transplanted cells have shown the characteristics of LCs. In the CM-DFs group, RFP+ cells were found to colonize the interstitium, but no cells expressed any of the LCs markers (Figure 3B). In addition, 9.17 ± 1.98% of the RFP+ cells in the CM-SLCs group were positive for the proliferation marker Ki67 (Figure 3C and S7).

Long-term survival of transplanted cells relies on the formation of connections between the graft and the host vascular system [43, 65]. Here, we observed that the transplanted cells were connected to host vessels, as evidenced by anti-Cd31, von Willebrand Factor (vWF), and VEGF Receptor 2 (VEGFR2) immunostaining without RFP co-expression (Figure 3D and S8). In addition, cell adhesion formation is associated with transplanted cell survival [66, 67]. As shown in Figure 3E, the transplanted RFP+ cells connected with endogenous LCs through the gap junction protein Connexin 43. These results suggest that CM-SLCs could engraft, survive and integrate into the host microenvironment in the aging testes of TD monkeys.

**CM-SLCs transplantation promotes spermatogenesis**

Intratesticular testosterone is essential for spermatogenesis [68, 69], and spermatogenic dysfunction is associated with the aging of LCs [63, 70]. To evaluate the impact of CM-SLCs transplantation on spermatogenesis, we performed semen analysis. The CM-SLCs group showed a significant increase in the sperm concentration (Figure 4A), total sperm count (Figure 4B), motile sperm concentration (Figure 4C) and total motile sperm count (Figure 4D) within 6-8 weeks post transplantation (n=7). In contrast, none of these sperm parameters showed a significant change from baseline in the CM-DFs group (n=4; Figure 4A-D).

Since testosterone is also known to be critical for the completion of meiosis [71], we used immunofluorescence staining to examine the expression of the meiosis markers SCP1 and SCP3. Our results showed that SCP1+ and SCP3+ cells were significantly increased in the testis after transplantation of CM-SLCs but not CM-DFs (Figure 4E-H). Overall, these results demonstrated that the autologous transplantation of CM-SLCs could partially improve spermatogenesis in TD monkeys.

**CM-SLCs transplantation ameliorates TD-related symptoms**

A decrease in testosterone is associated with many symptoms, including obesity [72] and decreases in muscle mass, strength, physical function, bone mass and sexual function [3]. To assess the effects of cell transplantation, we detected testosterone deficiency-related symptoms during the study. There was no significant change in body weight for the CM-DFs group (n=3), but this parameter decreased in the CM-SLCs group (n=4) (Figure 5A). Using dual-energy X-ray absorptiometry (DXA), we investigated whether CM-SLCs transplantation resulted in changes in fat and/or lean mass (Figure 5B and S9B). The lean body mass was unchanged in both groups, but the lean percentage decreased significantly in the CM-SLCs group (n=4), whereas no treatment-related change was detected in the CM-DFs group (n=3) (Figure 5B and S9B). The lean body mass was unchanged in both groups, but the lean percentage significantly increased in the CM-SLCs group (n=4) (Figure 5C and S9C). As previously reported, TD was associated with marked decreases in muscle strength and exercise capacity [73]. After transplantation, the maximum grip strength increased starting at week 6 post transplantation in the CM-SLCs group (Figure 5D). In contrast, little change in this parameter was seen among CM-DFs-injected TD animals (Figure 5D). Additionally, exercise capacity notably increased by 8
weeks after CM-SLCs transplantation, but no such increase was detected in the CM-DFs group (Figure 5E).

Figure 3. Transplanted CM-SLCs regenerate Leydig cells in the testes of monkeys with TD. (A, B) Immunostaining shows the accumulation of RFP+ CM-SLCs (A), CM-DFs (B) and StAR, 3β-HSD or CYP11A1 in the testicular interstitium of aged monkeys, as assessed at week 8 after transplantation. Scale bar, 40 µm. (C) Proliferation of transplanted CM-SLCs was demonstrated by staining for Ki67 at week 8 after transplantation (positive cells are indicated by arrow). T=Seminiferous tubule; Scale bar, 30 µm. (D) Vascularization of the transplanted CM-SLCs by host microvessels, as demonstrated by staining of endothelial cells for CD31. Scale bar, 30 µm. (E) Expression of the gap junction protein Connexin 43 (Cx43) between the transplanted CM-SLCs and host LCs (indicated by arrow). Nuclei were counterstained with DAPI (blue); Scale bar, 10 µm.
Figure 4. CM-SLCs transplantation promotes spermatogenesis. (A-D) The sperm concentration (A), total sperm number (B), motile sperm concentration (C), and total motile sperm number (D) were analyzed before and after cell transplantation (n=4 in the CM-DFs group, n=7 in the CM-SLCs group). (E, G) Meiotic spermatocytes were observed by immunofluorescence staining for SCP1 (E) and SCP3 (G) antibodies. Scale bar, 75 µm. (F, H) Quantitative analysis showing the percentage of SCP1-positive cells (F) or SCP3-positive cells (H) in the seminiferous tubules of the testis. Three sections per slide and three slides per testis were counted. Pre-Tx=before transplantation, Post-Tx=after transplantation. Data are expressed as the mean ± sem and were analyzed by Student’s t-test. * P < 0.05, ** P < 0.01, NS=not significant.

Previous studies linked TD to reduced bone mineral density (BMD), which can be improved by testosterone replacement treatment [8, 9]. Using DXA (Figure 5F), we observed that CM-SLCs transplantation was associated with a mean 6.05% increase in BMD in the total hip 8-10 weeks after transplantation, whereas the same parameter decreased by 0.79% in the CM-DFs group (Figure 5G). Our analysis of bone parameters showed that the mean serum osteocalcin level increased in the CM-SLCs group (n=4), with this difference reaching statistical significance at week 8 post transplantation (Figure 5H). In contrast, no such change was observed in the CM-DFs group (n=3). Neither group showed any transplantation-related difference in the serum concentrations of calcium or β-crosslaps (Figure 5I-J). Taken together, the observed improvements in body composition, strength, exercise capacity and BMD revealed that CM-SLCs transplantation has rejuvenating benefits in treating TD.
Figure 5. CM-SLCs transplantation relieves TD-related symptoms. (A) Dual-energy X-ray absorptiometry (DXA) whole-body imaging was performed. (B, C) Body fat (B) and lean body percentage (C) were calculated based on the DXA results. (D) The maximum grip strength of the two groups was analyzed before transplantation (0 week) and at week 6 after treatment. (E) The maximum climbing speeds of the both groups were analyzed before and after transplantation. (F) DXA images of the left hip during the study. (G) Total bone mineral density (BMD) of the left hip was calculated based on the DXA images. (H-J) The serum concentrations of osteocalcin (H), β-crosslaps (I) and calcium (J) were measured before and after cell transplantation (n=3 in the CM-DFs group, n=4 in the CM-SLCs group). Pre-Tx=before transplantation, Post-Tx=after transplantation. Data are expressed as the mean ± sem and were analyzed by Student’s *t*-test. * P < 0.05, ** P < 0.01, NS=not significant.
Discussion

We herein report the first proof-of-concept preclinical study demonstrating that autologous SLCs can engraft, survive, increase testosterone levels and relieve the relevant symptoms of TD in an NHP model based on short-term observations. Thus, a larger cohort with long-term follow-up needs to be performed to assess the translational feasibility of autologous SLCs transplantation for treating TD.

SLCs have been isolated and characterized from rat [29], mouse [32], pig [74] and human testes [35, 59]. Unlike most rodents but consistent with human males, rhesus macaques experience significant age-related declines in circulating testosterone [75, 76], indicating that NHPs are ideal animal models for the clinical development of SLCs-based therapies. However, knowledge of NHP SLCs was lacking until the present study. Cynomolgus macaques share high genomic sequence identity with humans, and this similarity reminds us that CD271, a previously reported marker of human SLCs [35], could be used to identify and isolate SLCs from monkeys. As illustrated in the current study, CD271+ cells not only expressed the known SLCs markers Nestin and PDGFRα but also could continuously proliferate and differentiate into mesenchymal lineage cell types. Moreover, we demonstrated that CD271+ cells could differentiate into functional LCs that secreted considerable testosterone. Due to the similar characteristics between the CD271+ cells derived from monkey testis and human SLCs [35], this population of cells was identified as CM-SLCs. Although previous studies have demonstrated that SLCs could be isolated from testis samples of pups or young adults [29, 32, 35], one major concern needs to be addressed regarding whether SLCs can be isolated and expanded from elderly patients for autologous transplantation because TD is an age-associated disease [61]. In the present study, we successfully isolated CM-SLCs using minimal testicular biopsies from elderly cynomolgus monkeys and produced these cells at a clinical scale (more than 3×10^11 cells at P10) in the expansion medium, which provides new clues for further development of human SLCs transplantation as a clinical therapy for TD.

Many studies have shown that SLCs transplantation significantly restored testosterone production and improved spermatogenesis in animal models, including aged or LCs-disrupted rodents [31-34]. Because large-animal models are critical for examining the safety and feasibility of experimental therapies before they are translated to the clinic [41], we screened 30 elderly monkeys (19 to 23 years old) and enrolled 11 of them with the indicators of age-associated TD for evaluating the therapeutic potential of autologous cell transplantation. CM-SLCs, rather than CM-DFs, significantly increased the serum testosterone level, indicating that these cells could potentially be used to treat aging-related TD. The circulating concentration of testosterone exhibits the appropriate circadian rhythm [76] and can be modulated by the HPG axis [3]. Here, we observed that monkeys transplanted with CM-SLCs appeared to display a normal daily rhythm of testosterone secretion. Besides, when the monkeys in the SLCs-transplanted group were administered decapreptyl, secretion of testosterone showed the typical pattern of increasing at the beginning and decline thereafter, suggesting that transplanted CM-SLCs were under the regulation of the HPG axis. Although testosterone replacement can help relieve the symptoms of hypogonadism [72, 73], this treatment can result in a reduction in intratesticular testosterone production and disruption of spermatogenesis [18-20]. In the present study, we demonstrated that CM-SLCs transplantation partially recovered spermatogenesis in TD monkeys. Although there was no statistical significance, semen parameters in monkeys transplanted with CM-DFs showed the growth trend, compared with the pre-transplanted animals. We speculate this might be due to the paracrine benefits of CM-DFs to the ageing microenvironments. As previously reported, DFs could secret a large number of cytokines, including fibroblast growth factor 2 (FGF2), stem cell factor (SCF) and hepatocyte growth factor (HGF) [77]. FGF2 is bona fide self-renewal factors for SSCs. Moreover, FGF2 also modifies germline niche functions right for spermatogonial differentiation [78]. It has been reported that SCF is required for maintenance of differentiated germ cells [79]. In addition, HGF could modulate germ cell metabolic activities in vitro, promoting germ cell proliferation while inhibiting apoptosis of germ cells [80]. Collectively, these studies indicated that the transplanted CM-DFs may promote spermatogenesis through paracrine factors to some degree. Moreover, for the first time, the short-term restoration of testosterone levels after CM-SLCs transplantation ameliorated the TD-relevant symptoms with respect to body composition, strength, exercise capacity and BMD. These results indicated that SLCs have the potential to alleviate relevant symptoms of TD, which have not yet been examined for SLCs in previous studies [31-34]. Along with testosterone recovery, we also observed that monkeys transplanted with CM-SLCs showed an improving tendency in sexual function (Figure S9D-K). While these data were not statistically significant, they exhibited a high degree of animal-to-animal consistency and thus would be
likely to reach statistical significance in studies involving larger numbers of animals in the future [43].

Chemotherapy and radiation treatments for cancer or other conditions can result in the loss of both spermatogenesis and LC function [81]. Therefore, most patients suffer from TD, increased body fat, decreased libido and infertility [82]. Currently, adult patients have the option to preserve their future fertility by semen cryopreservation, while for prepubertal boys faced with gonadotoxic treatments, testicular tissue fragments can be cryopreserved for potential autografting, in vitro maturation, and SSCs auto-transplantation with the aim of fertility restoration [83-85]. However, only a few attentions have been paid to the dysfunction of LCs [86]. From the current data, cryopreservation of a testicular biopsy taken before the initiation of cancer treatment followed by in vitro propagation of SLCs and subsequent auto-transplantation of these stem cells after cancer treatment, could be suggested as an approach to treat TD-associated symptoms in cancer survivors. In addition, the risk of malignant cell contamination and disease re-introduction to the host should be noticed in the autologous SLCs transplantation scheme, especially for patients with metastasizing tumors. In the present study, flow cytometry sorting was conducted based on the difference in cell surface markers to isolate and enrich CD271+ SLCs, which may provide a method to remove malignant cells.

The principal limitation of this study is the recovery of testosterone levels in a relatively short period after CM-SLCs transplantation (8 weeks), which may be due to the dramatic decrease in the number of RFP+ cells in the interstitium 12 weeks after transplantation (Figure S6). Previous studies have demonstrated that stem cells derived from aged animals showed cell-autonomous defects in proliferation and differentiation compared with their counterparts from young donors [87, 88]. Moreover, the aging microenvironment has been shown to dictate stem cell behavior [89]. Similarly, Curley M, et al. reported that age-related disruption of the testicular microenvironment or wider endocrine milieu likely plays a critical role in LC dysfunction [90]. To improve the therapeutic effects of SLCs transplantation, we need to develop better ways to rejuvenate aged SLCs in vitro and improve the aging microenvironment in vivo in future studies.

Conclusion

We first isolate and characterize cynomolgus monkey SLCs and demonstrate that autologous SLCs transplantation can increase testosterone levels and relieve relevant symptoms of TD in a primate model for at least 8 weeks. These findings support the need for large-scale studies with long-term follow-up to assess the translational feasibility of autologous SLCs for TD patients.

Abbreviations

17β-HSD: 17-beta-hydroxysteroid dehydrogenase; 3β-HSD: 3-beta-hydroxysteroid dehydrogenase; bFGF: basic fibroblast growth factor; BMD: bone mineral density; BSA: bovine serum albumin; BT: bioavailable testosterone; CM-DFs: cynomolgus monkey dermal fibroblasts; CM-SLCs: cynomolgus monkey SLCs; CYP11A1: cytochrome p450 family 11 subfamily A member 1; DXA: dual-energy X-ray absorptiometry; EGF: epidermal growth factor; FBS: fetal bovine serum; FT: free testosterone; GnRHa: agonist of gonadotropin-releasing hormone; IGFI: insulin-like growth factor 1; ITS: insulin-transferrin-sodium selenite; LCs: Leydig cells; LH: luteinizing hormone; LHR: luteinizing hormone receptor; LIF: leukemia inhibitory factor; NEAA: nonessential amino acids; NHP: non-human primate; OSM: oncostatin M; PBS: phosphate-buffered saline; PDGF-AA: platelet-derived growth factor AA; PDGF-BB: platelet-derived growth factor BB; RFP: red fluorescent protein; SF-1: steroidogenic factor 1; SLCs: stem Leydig cells; SSCs: spermatogonial stem cells; StAR: steroidogenic acute regulatory protein; TD: testosterone deficiency; TRT: testosterone replacement therapy; TT: total testosterone.

Supplementary Material

Supplementary figures, tables, movie legend. http://www.thno.org/v10p8705s1.pdf
Supplementary movie. http://www.thno.org/v10p8705s2.mp4

Acknowledgements

This work was supported by The National Key Research and Development Program of China (2018YFA0107200, 2017YFA0103802, 2018YFA0801404, 2017YFA0103403); the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16020701); The National Natural Science Foundation of China (31771616, 81671449, 81871110, 81571489, 81971372); Frontier and Innovation of Key Technology Project in Science and Technology Department of Guangdong Province (2019B020235002, 2019B020234001, 2016B030229002, 2017B020231001, 2016B030230001); the Natural Science Foundation of Guangdong Province, China (2018B030311039); Key Scientific and Technological Program of Guangzhou City (202007030011, 201704020223, 201604020189); the Fundamental Research Funds for the Central Universities
Author Contributions

A.P.X., C.D. and Q.K. conceived, organized and supervised the whole project. K.X., H.C., X.F., Y.G., R.D., P.L., Y.Z. and C.W. performed cell culture and transplantation. K.X., J.W., H.C., X.F., M.Z., Y.W., Y.Z., G.L., X.T., X.S., C.W., Y.Z. and W.L. contributed to measure the effect of treatment and analyzed data. A.P.X., C.D., Q.K., J.W., and K.X. wrote the manuscript with the help from all the authors.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Wu FC, Tajer A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363: 1251-61.
2. Hultaniemi I, Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat Rev Urol. 2011; 8: 335-44.
3. Basaria S. Male hypogonadism. Lancet. 2014; 383: 1250-63.
4. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016; 374: 611-24.
5. Finkelstein JS, Lee H, Burnett-Bowie SA, Fallsia JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013; 369: 1011-22.
6. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009; 94: 1991-2001.
7. Sterner TW, Basaria S, Trautadottir T, Harman SM, Percina K, Li Z, et al. Effects of Testosterone Supplementation for 3 Years on Muscle Performance and Physical Function in Older Men. J Clin Endocrinol Metab. 2017; 102: 583-93.
8. Vanderschueren D, Laurent MR, Claessen F, Gielen E, Lagerquist MK, Vandeperu L, et al. Sex steroid actions in male bone. Endocr Rev. 2014; 35: 906-94.
9. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Emerud KE, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017; 177: 471-9.
10. Ramasamy R, Wilken N, Scovell JM, Lipshultz LI. Effect of testosterone supplementation on symptoms in men with hypogonadism. Eur Urol. 2015; 67: 176-7.
11. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018; 103: 1715-44.
12. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Lessons From the Testosterone Trials. Endocrinol Rev. 2018; 39: 369-86.
13. Vigen R, O'Donnell CJ, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Spermatogonial stem cell transplantation into rhesus testes regenerates rhesus spermatogenesis producing functional sperm. Cell Stem Cell. 2012; 11: 715-26.
14. Hermann BP, Sukhwani M, Winkler F, Piscarella JN, Peters KA, Shen Y, et al. Spermatogonial stem cell transplantation into rhesus testes regenerates rhesus spermatogenesis producing functional sperm. Cell Stem Cell. 2012; 11: 715-26.
15. Liu YW, Chen B, Yang X, Fugate JA, Kalucki FA, Futakuchi-Tsudhia A, et al. Human embryonic stem-cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat Biotechnol. 2018; 36: 597-605.
16. Jiang B, Fu X, Yan L, Li S, Zhao D, Wang X, et al. Replacement of human p75-positive stem Leydig cells replace disrupted Leydig cells for testosterone production. Cell Death Dis. 2017; 8: e2832.
17. Colman RJ. Non-human primates as a model for aging. Biochim Biophys Acta Gen Subj. 2018; 1844: 2733-41.
18. Shively CA, Clarkson TB. The unique value of primate models in translational research. Nonhuman primate models of women's health: introduction and overview. Am J Primatol. 2006; 71: 715-21.
19. Mattison JA, Vaughan KL. An overview of nonhuman primates in aging research. Exp Gerontol. 2010; 45: 1-5.
20. Bailer B, Belanger A. The cynomolgus monkey (Macaca fascicularis) is the best animal model for the study of steroid glucuronidation. Journal of Steroid Biochemistry and Molecular Biology. 2003; 85: 235-45.
21. Zhang XS, Lue YH, Guo SH, Yuan JX, Hu ZY, Han CS, et al. Expression of estrogen receptor alpha and beta in human testis: differential linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008; 93: 2377-45.
22. Ziskin BR, Chen H. Regulation of Leydig cell steroidogenic function during aging. Biochim Biophys Acta. 2003; 163: 977-91.
50. Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, et al. Human iPSC cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature. 2017; 548: 592-6.

51. Hussein A. Evaluation of diagnostic tests biopsy and the repetition of testicular sperm extraction surgeries in infertility patients. Fertil Steril. 2013; 100: 88-93.

52. Zhang ZJ, Wang J, Chen Z, Zhang Y, Gao Y, Su Z, et al. Transplantation of CD133(+) Stem Leydig Cells: A New Strategy for the Treatment of Testosterone Deficiency. Stem Cells. 2017; 35: 1222-32.

53. Bourget C, Fenino A, Franz C, Longo C. Estrogen and androgen dynamics in the cynomolgus monkey. Endocrinology. 1988; 122: 202-6.

54. Mou H, Vinarsky V, Tata PJ, Braxasakis Ch, Crooke AK, et al. Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells. Cell Stem Cell. 2016; 19: 217-31.

55. Luo J, Yang Y, Zhang T, Su Z, Yu D, Lin Q, et al. Nasal delivery of nerve growth factor rescue hypogonadism by up regulating GnRH and testosterone production in young rhesus macaques (Macaca mulatta). Biopol. Biomed. Biophys. 2018; 83: 635-40.

56. Mattison JA, Colman RB, Beasley TM, Allison DB, Kemnitz JW, Roth GS, et al. Caloric restriction improves health and survival of rhesus monkeys. Nat Commun. 2017; 8: 14063.

57. Hamalainen A, Dammhahn M, Aujard F, Kraus C. Losing grip: Senescent dermal fibroblasts on melanocyte pigmentation. J Dermatol Sci. 2017; 88: 159-66.

58. Sitzmann BD, Leone EH, Mattison JA, Ingram DK, Roth GS, Urbanski HF, et al. Human testicular peritubular cells host putative stem Leydig cells with a steroidogenic capacity. J Clin Endocrinol Metab. 2014; 99: E1227-35.

59. Gupta AA, Donen RM, Sung L, Boydell KM, Lo KC, Stephens D, et al. Testicular Biopsy for Fertility Preservation in Prepubertal Boys with Cancer: Identifying Preferences for Procedure and Reactions to Disclosure Practices. J Urol. 2016; 196: 192-214.

60. Beattie MC, Adekola L, Papadopoulos V, Chen H, Zirkin BR. Leydig cell aging with Normal Total Testosterone. J Clin Endocrinol Metab. 2016; 101: 2647-57.

61. Lee AP, Roth MY, Nya-Ngatchou JJ, Lin K, Walsh TJ, Page ST, et al. Decrease in semen quality and Leydig cell function in infertile men: a longitudinal study. Hum Reprod. 2010; 25: 2160-8.

62. Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Snyder CN, et al. Testicular fine-needle aspiration for the assessment of intratesticular hormone deficiency. J Clin Endocrinol Metab. 2010; 95: 3806-13.

63. Luo J, Yang Y, Zhang T, Su Z, Yu D, Lin Q, et al. Nasal delivery of nerve growth factor rescue hypogonadism by up regulating GnRH and testosterone production in young rhesus macaques (Macaca mulatta). Biopol. Biomed. Biophys. 2018; 83: 635-40.

64. Antonio L, Wu FC, O'Neill TW, Pye SR, Ahern TB, Laurent MR, et al. Low Free Testosterone Is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. J Clin Endocrinol Metab. 2016; 101: 2647-57.

65. Judson RN, Quarta M, Oudhoff MJ, Soliman H, Yi L, Chang CK, et al. Inhibition of Methyltransferase Setd7 Allows the In vitro Expansion of Myogenic Stem Cells with Improved Therapeutic Potential. Cell Stem Cell. 2017; 20: 347-62.

66. Cosgrove BD, Gilbert PM, Porpiglia E, Mourikoti F, Lee SP, Corbel SY, et al. Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat Med. 2014; 20: 253-64.

67. Catizone A, Ricci G, Del Bravo J, Galdieri M. Hepatocyte growth factor modulates in vitro survival and proliferation of germ cells during postnatal testis development. J Endocrinol. 2006; 199: 137-46.

68. Chemaitilly W, Liu Q, van Iersel L, Nesi K, Li Z, Wilson CL, et al. Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study. J Clin Oncol. 2019; 37: 3018-31.

69. Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, et al. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab. 2007; 92: 3476-82.

70. Onofre J, Baert Y, Faes K, Goossens E. Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation. Hum Reprod Update. 2016; 22: 744-61.

71. Kenney LB, Antal Z, Ginsberg JP, Hoppe BS, Bober SL, Yu RN, et al. Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Fertility: Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Fertility. J Clin Oncol. 2019; 37: 3018-31.

72. Judson RN, Quarta M, Oudhoff MJ, Soliman H, Yi L, Chang CK, et al. Inhibition of Methyltransferase Setd7 Allows the In vitro Expansion of Myogenic Stem Cells with Improved Therapeutic Potential. Cell Stem Cell. 2017; 20: 347-62.